Immune checkpoint therapy for pancreatic cancer

doi:10.3748/wjg.v22.i43.9457

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 43

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9896)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

900

WORD

212

HTML

5363

Figures (1-2)

189

Tables (1-5)

184

Sum=6848

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

485

Download

432

Sum=917

Publishing Process of This Article

Item

Count

Browse

993

Download

1138

Sum=2131

Nov 21, 2016 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (65)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Nov 21, 2016; 22(43): 9457-9476
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9457

Table 1 Clinical trials on cytotoxic T lymphocyte antigen 4

Target molecule	Drug name	Study phase	Study design	Status	Condition	Intervention	Cohort	Estimated enrollment	Dose	End point	Study Arm	Adverse event	Response	Survival	Ref.
CTLA-4	Ipilimumab (BMS-734016/MDX-010)	1	NA	Active	PC	Palliative	Locally advanced	28	DE	Safety (MTD, DLT)	Ipilimumab, Gemcitabine	NA	NA	NA	NCT01473940
CTLA-4	Ipilimumab (BMS-734016/MDX-010)	1	NA	Not recruiting	PC	Palliative	Metastatic	28	DE	Efficacy (RR, PFS, OS)	Ipilimumab, Gemcitabine	NA	NA	NA	NCT01473940
		2	Randomized	Recruiting	PC	Palliative	Metastatic	92	3 mg/kg	Safety (AE)	Ipilimumab, GVAX (Arm A)	NA	NA	NA	NCT01896869
		2	Randomized	Recruiting	PC	Palliative	Metastatic	92	3 mg/kg	Efficacy (OS, PFS, ORR, DoR)	FOLFIRINOX (Arm B)	NA	NA	NA	NCT01896869
	Tremelimumab (CP-675/CP-675,206)	2	NA	Recruiting	PC, BlC, BC	Palliative	Metastatic	77	NA	Safety	Tremelimumab (Arm A)	NA	NA	NA	NCT02527434
										Efficacy (ORR, DoR, DCR, PFS, OS, BoR)	Durvalumab (Arm B)
											Tremelimumab, Durvalumab (Arm C)
		2	Randomized	Recruiting	PC	Palliative	Metastatic	130	NA	Safety	Durvalumab (Arm A)	NA	NA	NA	NCT02558894
										Efficacy (ORR, DoR, DCR, PFS)	Durvalimab, Tremelimumab (Arm B)
										PK
										Antidrug Antibody Presence
		1	Randomized	Recruiting	PC, NSCLC, HNSCC	Palliative	Locally advanced	108	NA	Safety (AE, DLT)	Durvalumab, Mogamulizumab (Arm A)	NA	NA	NA	NCT02301130
		1	Randomized	Recruiting	PC, NSCLC, HNSCC	Palliative	Metastatic	108	NA	Safety (AE, DLT)	Tremelimumab, Mogamulizumab (Arm B)	NA	NA	NA	NCT02301130
		1	Non-randomized	Recruiting	PC, NSCLC, BC, MM	Palliative	Metastatic	30	1 mg/kg	Safety (AE)	Durvalumab, Tremelimumab, Radiotherapy	NA	NA	NA	NCT02639026
		1	Non-randomized	Recruiting	PC, NSCLC, BC, MM	Palliative	Metastatic	30	1 mg/kg	Efficacy	Durvalumab, Tremelimumab, Radiotherapy	NA	NA	NA	NCT02639026

ORR: Overall response rate; DLT: Dose limiting toxicity; AE: Adverse event; MTD: Maximum tolerance dose; NA: Not available.

Citation: Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22(43): 9457-9476
URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9457.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9457